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Optimizing outcomes in ADHD treatment:
from clinical targets to novel delivery systems
Gregory W. Mattingly,1,2* and Richard H. Anderson2
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Our knowledge and understanding of the underlying neurobiology and symptomatic expression of ADHD has advanced
dramatically over the past decade. Associated with these advances has been a similar explosion of new treatment
options to individualize treatment for our patients.
This article will:
∙ review strategies to measure ADHD symptoms and functional difficulties while seeking to achieve full symptomatic
remission throughout the day
∙ summarize recent findings regarding the management and prioritization of ADHD and comorbid conditions and
∙ discuss the various pharmacologic treatment options with a focus on recently developedmolecules and novel delivery
systems
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Introduction
While once considered a condition of hyperactive boys, our
knowledge and understanding of attention deficit hyper-
activity disorder (ADHD) and related conditions has
dramatically evolved over the last decade. Landmark studies
by Biederman, Faraone, and Adler among others have
changed and deepened our understanding of ADHD to
include a condition that not only affects boys but quite often
affects girls.1–4 The evolution of symptoms across the
lifespan and the concomitant neurologic changes that
underlie this symptomatic expression have similarly evolved.
More recently, landmark studies by Dalsgaard and others
have brought to light the significantly increased morbidity
and mortality associated with preschoolers, children, and
adults struggling with ADHD and associated conditions.5,6
This article will provide the following:
1. A more thorough understanding of data relating to
the long-term consequences of unrecognized and
undertreated ADHD both within an individual and
on a global basis
2. Ways to better identify and diagnose the various
clinical presentations across the lifespan
3. A better understanding of how to clinically manage
and prioritize the treatment of patients with ADHD
and comorbid conditions
4. A discussion of various pharmacologic treatment
options and newer novel delivery systems
5. Strategies to measure ADHD disorder throughout
the day and monitor improvement while seeking to
achieve full symptomatic remission
Consequences of ADHD Across the Lifespan
Attention deficit hyperactivity disorder (ADHD) is a
common neurodevelopmental disorder that affects
approximately 8–11% of school aged children, both in the
United States and throughout the rest of the developed
world.7 Initially considered primarily a condition of
hyperactive boys, it has come to be recognized as a condition
that affects both boys and girls and often persists from
childhood to adolescence and into adulthood.8 The classic
triad of hyperactivity, impulsivity, and inattention captures
many of the core aspects of ADHD but fails to capture
some of the difficulties surrounding executive function
and emotional reactivity, which collectively account for
much of the social, educational, occupational, and
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emotional impairment of the disorder. In early childhood
and throughout grade school, ADHD is diagnosed more
frequently in boys than girls; this is possibly related to the
higher expression of overt hyperactive symptomatology that
is found in preadolescent boys.4 ADHD patients with
predominantly inattentive symptoms are often overlooked,
misdiagnosed, or diagnosed 2–3 years later in life because
the overt outward marker of hyperactivity has often been
used to identify this condition.
Our basic understanding of the neurophysiology of
ADHD has advanced dramatically with landmark studies by
investigators such as Nora Volkow, who highlighted the
differences in dopamine transporter activity in children
with ADHD; Philip Shaw, who tracked maturation of the
prefrontal cortex in children with ADHD, and more recent
studies looking at the influence of genetic heritability and
environmental factors.2,8,9 These studies, taken in total,
show that ADHD is a highly genetic neurologic condition,
and it affects numerous cortical and subcortical pathways
that coordinate information processing, impulsivity, emo-
tional modulation, and neurochemical pathways which
modulate communication between these cortical regions.
ADHD has an overall genetic heritability of approximately
75%, ie, 3 out of 4 times there will be a genetic family
history. Environmental factors also influence our genes,
with epigenetic changes occurring in a number of our
children exposed to environmental stressors, such as
prenatal nicotine exposure, lead exposure, or severe
psychosocial trauma.10,11
Long-term, follow-up, longitudinal studies have
shown that ADHD children are at greater risk of
academic difficulties, emotional dysregulation with
oppositional defiant disorder tendencies, and emotional
volatility. Longitudinal imaging studies have shown
a 2- to 3-year delay in maturation of the prefrontal cortex
and associated pathways in children with ADHD as
compared to non-ADHD controls.9 It is therefore not
surprising that ADHD symptomatology continues to
evolve throughout childhood, adolescence, and into
early adulthood as the underlying neurophysiology of
the brain continues to mature and is influenced by
outside environmental demands, such as high school,
college, employment, and the social demands of adulthood.
By adolescence there is an increased rate of drug
and alcohol abuse, an increased rate of motor vehicle and
traffic-related difficulties, and a dramatically increased rate
of teenage pregnancy for ADHD individuals compared to
controls.12 Followed into adulthood, ADHD individuals
have lower occupational and economic performance;
have increased difficulty with financial management;
and have increased rates of psychiatric comorbidity, such
as depression, alcohol and drug abuse, emotional lability,
intermittent explosive disorder, and a variety of anxiety
disorders.13 Most importantly for ADHD adults, we
find increased rates of marital dysfunction and divorce,
dramatically worsened abilities to maintain ongoing
friendships and relationships, and significantly lower
evaluations of self-esteem and self-worth.12
Can Treatment Make a Difference?
Although classic ADHD studies have shown that both
behavioral and medical interventions can improve core
ADHD symptoms, there has been debate about the overall
long-term functional impact of ADHD interventions.
Studies by Biederman, Wilens, and others have shown that
consistent ADHD treatment decreased the rate of drug and
alcohol abuse later in life.14 Numerous studies in analog
classroom settings have shown improved concentration on
task-related activities, such as completing math problems,
and improvement on behavioral tasks measured by rating
scales such as the Swanson, Kotkin, Atkins, M-Flynn, and
Pelham scale (SKAMP).15
Studies by Dalsgaard and others have shown that ADHD
is associated with significantly increased morbidity and
mortality (Figure 1).5,6 These studies have found increased
rates of accidental injury requiring medical treatment and
injury requiring emergency room intervention. Utilizing
the Danish birth registry, Dalsgaard found that on a
nationwide basis, ADHD individuals had dramatically
increased mortality rates compared to the general popula-
tion. ADHD preschoolers had an 86% increased mortality
rate, school aged students had a 58% increased mortality
rate, and adults with ADHD had a 325% increased
mortality rate relative to non-ADHD individuals within
the same population.5 These studies went on to analyze
whether ADHD treatment within the overall population of
Denmark impacted these adverse outcomes. They found
that ADHD treatment was associated with an overall
decrease in accidental injury and medical utilization due
to accidents and trauma (Figure 2). On a nationwide basis,
they found a 25–37% decrease in emergency room
utilization among ADHD individuals receiving treatment
versus those not receiving treatment.6
ADHD Mortality Rate Ratios
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Lancet. 2015 May;385(9983):2190–6
FIGURE 1. ADHD Mortality Rates.5
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Diagnosis and Recognition of Symptoms
ADHD is a pervasive condition with symptoms that start in
childhood or adolescence. There are 18 classic symptoms.7
Nine of these symptoms involve primarily inattentive
or cognitive symptomatology, and 9 involve primarily
hyperactive or impulsive symptomatology. According to
Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-V) criteria, children with ADHD
must have a persistent pattern of inattention and/or
hyperactivity-impulsivity that interferes with functioning
or development with ≥6 inattentive symptoms for
an inattentive presentation, ≥6 hyperactive/impulsive
symptoms for a hyperactive/impulsive presentation,
or ≥ both 6 inattentive and 6 hyperactive/impulsive
symptoms to meet criteria for a combined presentation.
Longitudinal studies of ADHD children followed into
adulthood by Barkley and others have shown that ADHD
adults had difficulty remembering symptoms dating back to
early childhood and therefore the DSM-V diagnostic criteria
have been modified.12 For a diagnosis in late adolescence
or adulthood, several symptoms must have been present
before age 12, and there must continue to be ≥5
of 9 symptoms in either the inattentive, hyperactive/
impulsive, or in both domains for diagnosis.
Improving the accuracy of ADHD diagnosis and treatment
Clinical data and research evidence have highlighted the
need to shift from a subjective to a more objective measure
of ADHD diagnosis and treatment. A variety of fairly
sensitive and specific ADHD rating scales have been
developed to better define and measure ADHD symptoms,
both during initial diagnosis and throughout ongoing
treatment. While in no way substituting for a thorough
clinical evaluation, these scales help to do the following:
∙ Better quantify and define ADHD impairments during
the initial diagnosis
∙ Measure ADHD symptoms at various time points
throughout the day
∙ Track ADHD symptoms to make sure that overall
symptomatic improvement, symptomatic remission,
and functional normalization have been optimized for
each patient
∙ Save time by providing an objective measure of
symptom severity before meeting with a patient
Why should a clinician use ADHD rating scales?
Just as it is helpful for an internist to know an individual’s
blood pressure or hemoglobin A1c when diagnosing and
optimizing treatment for a hypertensive or diabetic
patient, ADHD rating scales can be similarly useful in
managing our patients (Table 1).
The ADHD-Rating Scale (ADHD-RS), the Vanderbilt,
and the Conner’s are examples of ADHD scales that have
been shown to be consistent diagnostic measures of core
ADHD symptoms and are sensitive to treatment effect.16–19
Various ratings of executive function, such as the Behavior
Rating Inventory of Executive Function (BRIEF), can be
utilized to measure executive function deficits, which
frequently cause impairment for ADHD individuals.20
Another group of scales has been developed to measure
ADHD symptoms and how they fluctuate throughout the
day. Analog Classroom andAnalogWorkplace settings have
been developed to measure ADHD symptoms and evaluate
how different treatment modalities improve symptoms over
the course of the day. In these settings, the 13-item SKAMP
is used to measure attention, behavior, and deportment
in children, and the Permanent Product Measure of
TABLE 1. ADHD screening and rating scales
Scales Notes
ADHD Rating Scale (ADHDRS) Ages 6–12; parent and teacher forms
Adult ADHD Self-Report Scale
(ASRS)
Adults; the first part is a screening test, the




Behavior Rating Inventory of
Executive Function (BRIEF)
Ages 5–18; parent and teacher forms




Used for screening, not diagnosis
Conners Adult Attention Deficit/
Hyperactivity Disorder Rating
Scale
Adult; investigator, observer, and self-report
forms
Daily Parent Rating of Evening and
Morning Behavior (DREMB)
Parent form
Permanent Product Measure of
Performance (PERMP)
Age-adjusted math problems; 10-minute
test
Swanson, Kotkin, Agler, M-Flynn,
and Pelham Scale (SKAMP)
Ages 7–12; teacher form
SNAP-IV Rating Scale-Revised
(SNAP-IV-R)
Ages 6–18; includes parent and teacher
forms
Vanderbilt ADHD Rating Scales Ages 6–12; parent and teacher forms
% Decrease in Emergency Room Visits With ADHD
Medication Treatment
Danish National Registery-Dalsgaard et al
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FIGURE 2. Decrease in emergency room visits with ADHD treatment.6
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Performance (PERMP) measures a child’s or adult’s ability
to sit and complete a series of basic math equations during
10 minutes; these tests are then repeated at various time
points throughout the day.15,21 The Daily Parent Rating of
Evening and Morning Behavior (DPREMB) evaluates
behaviors in themorning and evening.22 The Before School
Functioning Questionnaire (BSFQ) has been developed to
help clinicians better evaluate ADHD symptoms and
functional impairments, which frequently occur and cause
significant disruption during the morning hours.23
Goals for Treatment
ADHD medications have some of the highest effect sizes
of any medical intervention.24 Studies also demonstrate,
however, that response to specific medications is highly
individual. A patient may respond well to a methylphe-
nidate preparation but may fail to respond to or may
have significant adverse effects with an amphetamine
preparation. Studies show that some patients respond
equally well to either class, while other individuals have
a preferential response to either a methylphenidate
preparation or an amphetamine preparation.25 Children
who have experienced adverse effects or have failed
stimulants may go on to either tolerate or preferentially
respond to nonstimulants such as atomoxetine, guanfa-
cine XR, or clonidine XR. Finally, studies have shown
that combinations of nonstimulants with stimulants can
have beneficial effects for patients who were only partial
responders to a stimulant alone.26
Studies with all 3 classes of medications—
methylphenidates, amphetamines, and nonstimulants—
have highlighted that it is all too easy for clinicians to
settle for partial improvement while still leaving patients
with ongoing symptomatology. Clinical response has
often been defined as a 25–30% symptom improvement,
but this still leaves patients with ongoing and significant
symptomatic and functional impairment. Long-term
trials with sustained-release stimulants have shown
that 90–95% of patients achieve 30% symptomatic
improvement. Interestingly, clinicians interpret 30%
symptom improvement as “much” or even “very much
improved” on global clinical measures.27–30
Patients and clinicians may be tempted to be satisfied
with 30% improvement, even though the evidence is
clear that such minimal improvement almost inevitably
means continued functional impairment. For most
patients, further improvement is possible. Long-term
trials demonstrate that nearly 75–80% of patients can
achieve >50% symptom reduction and achieve sympto-
matic remission with an overall ADHDRS score of less
than 18, meaning that ADHDRS scores are mild or less
on average (Figure 3).31,32
In addition to overall symptom improvement, our
treatments must deliver symptomatic improvement at time
points where functional impairment is occurring for
our patients. Studies by Sallee, Whalen, Mattingly, and
others have shown that clinicians primarily focus on
consequences of ADHD during school and work while
overlooking impairments that occur at the beginning and
end of the day.33–35 Sallee33 found that 79% of caregivers
have discussed early morning functional impairments,
such as getting out of bed, getting dressed, self-hygiene,
eating breakfast, packing their backpack, and being able to
catch the bus, as being some of the most impairing issues
for their children with ADHD. Of these caregivers, 48%
indicated they had to wake up early in the morning to
administer ADHD medication before their child’s normal
wake time because of functional difficulties experienced
before their child’s medication had taken effect.33
Comorbid Conditions
Numerous studies in the U.S. and other countries around
the world have found that ADHD commonly presents with a
constellation of comorbid challenges and disorders.13,36
Young children with ADHD frequently have associated
learning disorders or developmental disabilities, such as
difficulties with sensory integration, problems with working
memory, speech and language delay, and difficulties with
reading comprehension. A baseline battery of neurocogni-
tive testing to detect specific learning challenges should be
considered in all school-age children with ADHD. Recogni-
tion of specific learning challenges can help to better
identify therapeutic interventions and academic accommo-
dations, which can be of great benefit for children struggling
with ADHD and associated learning difficulties.
Emotional impulsivity, oppositional behavior,
and poor frustration tolerance
Many children, adolescents, and adults with ADHD
struggle with symptoms associated with poor frustration
30%
50%
Clinical Response and Symptomatic Remission
Mattingly et al, Poster APA 2016
FIGURE 3. Clinical response and symptomatic remission with ADHD
treatment.32
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tolerance. These symptoms can present in childhood as
difficulty waiting, impatience with delays, or excessive
frustration when asked to shift from a preferred to a
nonpreferred task. Such frustration often leads to a sequence
of escalating emotional and behavioral dyscontrol, “melt-
downs” out of proportion to the task at hand, and emotional
fragmentation.37 Meltdowns may last only minutes, but they
leave the child, his or her family, and those around them
emotionally nonfunctional for far longer periods. At such
times, parents and caregivers may unintentionally worsen
outcomes by raising the level of negative emotional tone,
with angry scolding or excessive disciplining. Such “heat of
the moment” tactics usually only cause further fragmenta-
tion and decompensation. Caretaker strategies that model
calmness, promote emotional modulation, and preemptively
forecast transitions while strategically planning for potential
frustration have been shown to help minimize the frequency
and severity of emotional fragmentation.
Oppositional thoughts and behaviors can trouble
ADHD individuals of any age.12,38 Difficulties shifting
from preferred to nonpreferred tasks and impaired
recognition of the emotional impact of their behavior
on others frequently lead to such oppositional patterns in
ADHD individuals.39 Therapeutic techniques that teach
patients to “unstick” when locked into ineffective
behavioral or cognitive patterns, that foster abilities to
externalize and appreciate the emotional impact of their
behavior on others, and that improve the ability to
transition from preferred to nonpreferred tasks or
thoughts can lessen the tendency toward negative and
oppositional patterns and improve the functioning of
ADHD children, adolescents, and adults alike.
Comorbid mood and anxiety disorders
ADHD frequently presents with comorbid anxiety
disorders, mood disorders, and affective instability.
A number of rating scales have been developed to
help better ascertain and evaluate the presence of
child and adolescent depression, comorbid anxiety
conditions, and the possible emergence of bipolarity
in preadolescent, adolescent, and young adult patients.
Studies by Geller, Biederman, and others have
highlighted the diagnostic conundrum of ADHD in
the presence of significant mood disorders and
mood lability, and give guidance on how to better
recognize and diagnose childhood ADHD versus
underlying bipolar disorder. Geller et al40 found that
when preadolescent children with ADHD were
compared to children with bipolar disorder versus
non-emotionally impaired controls, 5 screening
questions emerged as the best way to help differentiate
ADHD children from those with bipolar disorder
(Figure 4). The five best discriminating questions were
as follows:
1. Racing thoughts
2. Decreased need for sleep
3. Elated mood
4. Grandiosity
5. Hypersexuality and hypersexual behavior
Of note, irritability and episodic, dysphoric mood
were not good discriminating items, since these were
frequently found both with bipolar children and with
children with classic ADHD.
FIGURE 4. Symptoms which differentiate Pre-pubertal Bipolar and ADHD.40
52 G. W. MATTINGLY AND R. H. ANDERSON
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1092852916000808
Downloaded from https:/www.cambridge.org/core. Washington University School of Medicine - St Louis, on 12 Apr 2017 at 02:07:24, subject to the Cambridge Core terms of use, available at
Studies looking at children who have ADHD plus
significant major depression are at increased chance of
eventually evolving into a bipolar spectrum illness, with
approximately with 25% of preadolescent ADHD comorbid
depression patients eventually developing bipolar
disorder.41 Signs of bipolarity, including the aforementioned
5 symptoms, along with family loading and discreet cycling
ofmood out of proportion to environmental stimulus should
be watched for as children with ADHD plus depression
progress throughout the life span. In adulthood, the
National Comorbidity Survey Replication Study showed
that 47% of adults with ADHD will have a comorbid anxiety
disorder, with nearly 1 in 3 ADHD adults also meeting
criteria for social phobia and between 5–10% meeting
criteria for generalized anxiety disorder, panic disorder,
and posttraumatic stress disorder. In the mood disorder
spectrum, the National Comorbidity Study found that 38%
of ADHD adults meet criteria for a major mood disorder,
with 15-–20% meeting lifetime criteria for bipolar disorder,
15–20% meeting criteria for comorbid major depression,
and 12% meeting criteria for chronic dysthymia.13
In the childhood arena, 2 more recent DSM-V diagnostic
dilemmas involve the co-occurrence of autism spectrum
disorders and ADHD and the newly established diagnosis of
“disruptive mood dysregulation disorder.”7,41 In DSM-IV,
the comorbidity of autism and ADHD could not officially be
diagnosed concurrently.39 With changes to DSM-V, it has
now been recognized that approximately 50% of children in
the autism spectrum will have a comorbid diagnosis of
ADHD. Such children tend to be exceptionally sensitive to
adverse effects of traditional ADHD medications, and these
individuals should be started on extremely low doses of
medications that are as smoothly released as possible
to minimize emotional lability, tics, twitches, insomnia,
agitation, or emotional fragmentation, which frequently
occur in these comorbid autism spectrum individuals. In
addition to poorly tolerating adverse effects of traditional
ADHD medication, these individuals also frequently have
tactile and swallowing difficulties. Alternative formulations
of ADHDmedications may be desired in this population due
to difficulties with sensory, tactile, and swallowing issues.
Such preparations include medications that can be
sprinkled, dissolved in liquid, come in liquid form, or orally
disintegrating formulation. DSM-V defines “disruptive
mood dysregulation disorder” as a childhood condition
where the children are “irritable or angry most of the day
nearly every day, have severe temper outbursts an average of
3 or more times per week and have trouble functioning due
to irritability inmore than one environment”with symptoms
occurring consistently for a minimum of 12 months.
Prioritization for treatment among comorbid conditions
The old adage of “treat mood and anxiety first”
before treating ADHD has long been considered the
recommended standard of care when confronted
with patients with ADHD and significant mood or
anxiety symptoms. Recent findings by Chen et al42 from
a nationwide longitudinal study of ADHD and comorbid
major depression (MDD/ADHD) may cause clinicians to
rethink this strategy. Their study identified 1,891
patients with MDD/ADHD and compared them with
1,891 age- and sex-matched patients with major depres-
sion only. Patients with MDD/ADHD had a 232%
increased risk of treatment resistance to multiple
antidepressants compared with patients with major
depression without ADHD. Their study went on to find
that individuals receiving regular treatment for ADHD
had a significantly lower risk for antidepressant
treatment resistance. They concluded that patients
who had dual diagnoses of major depression and
attention deficit hyperactivity disorder were more likely
to have treatment resistance to antidepressants, and that
prompt and regular treatment for attention deficit
hyperactivity disorder would reduce this risk.42 This
study highlights the fact that when ADHD symptomato-
logy is driving functional impairments and exacerbating
underlying mood disorders, anxiety disorders, or
substance abuse, concomitant treatment of ADHD and
these associated conditions often yields the best
overall therapeutic response. Imagine the case scenario
of a mother overwhelmed with difficulties due to
forgetfulness, distractibility, and poor time management
who develops significant anxiety symptoms as a result of
her underlying functional difficulties due to ADHD.
Similarly imagine a depressed college student struggling
with underlying ADHDwho has difficulty staying focused
and remembering what is discussed in the lecture hall,
then returning to his or her dorm room and struggling
with cognitive processing and information processing
while studying for an upcoming exam. Finally imagine an
adult with ADHD with comorbid substance abuse who is
struggling with issues surrounding emotional impulsivity
and poor frustration tolerance trying to maintain a path
to sobriety while struggling with underlying symptoms of
ADHD. Careful, judicious treatment of all of these
conditions may improve not only the underlying ADHD
symptomatology, but may also provide a path to stability
for treatment of the associated comorbidities. In the
aforementioned cases, attempts should be made to
minimize emotional side effects of ADHD treatment
while monitoring for potential abuse or misuse of
stimulant medications. Numerous studies have shown
that long-lasting stimulants and nonstimulant medica-
tions will often stabilize emotional impulsivity and
can be used carefully in such populations. Slightly
more controversial would be the use of low doses of
psychostimulants for children and adolescents struggling
with bipolar disorder and ADHD. Pediatric and
adolescent bipolar studies have shown that low-dose
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stimulants used in combination with bipolar medications
can be combined when needed to stabilize children and
adolescents struggling with comorbid ADHD and bipolar
disorder.
Immediate-Release, Sustained-Release, Delayed-
Release: Choosing Between Medication Options
The last several years have seen an explosion in stimulant
delivery systems available for ADHD treatment
(Tables 2–5). Stimulants are now considered the first
line pharmacologic treatment option for individuals
with ADHD.43,44 ADHD treatment has progressed
from what was initially a decision between short-acting
methylphenidate versus short-acting amphetamine, each
of which required dosing several times per day in order
to maintain therapeutic efficacy. Various strategies
have been developed by pharmaceutical manufacturers
to avoid the mid-day and intraday dosing. Early modifica-
tions involved slow-release wax matrix technologies,
which, while extending the duration of action, continued
to have difficulties with variable release patterns
from day to day and from patient to patient depending
on pH-related factors, gastric motility, and meal effects.
The next set of sustained-release medications involved
beaded technologies, where a certain percentage
of medication was released in short-acting, immediate-
release beads while another percentage of beads was
coated with a pH-dependent layer that would begin to
release approximately 4 hours later in the less acidic
small intestine, providing clinical efficacy for approxi-
mately 8–10 hours. These beaded technologies allowed
for adjustment of what percent of beads would be
TABLE 2. Amphetamine formulations
Formulations Brand names Duration Dosing Approval
Immediate-release d-amphetamine tablet Zenzedi 4–5-hr 2nd dose at lunch Ages 3–16
Immediate-release d-amphetamine oral solution ProCentra
(previously Liquadd)
4–6-hr 2nd dose at lunch Ages 3–16
Extended-release d-amphetamine capsule Dexedrine 6–8-hr Once-daily in the morning Ages 3–16
Lisdexamfetamine dimesylate capsule Vyvanse Up to 12-hr
Peak at 3.5-hr
Once-daily in the morning Ages 6–17 and adults
Immediate-release d,l-amphetamine tablet Adderall 4–6-hr 2nd dose at lunch Ages 3–12
Immediate-release d,l-amphetamine tablet Evekeo 6–hr 2nd dose at lunch Ages 3–12, ages 13–17, and adults
Extended-release d,l-amphetamine orally disintegrating tablets Adzenys XR-ODT 8–12-hr
Peak at 5-hr
Once-daily in the morning Ages 6–12, ages 13–17, and adults
Extended-release d,l-amphetamine oral suspension Dyanavel XR 10–12-hr
Peak at 4-hr
Once-daily in the morning Ages 6–17
Extended-release d,l-amphetamine tablet Adderall XR 8–12-hr
Peak at 6–8-hr
Once-daily in the morning Ages 6–12, ages 13–17, and adults
TABLE 3. Methylphenidate formulations
Formulations Brand names Duration Dosing Approval
Immediate-release d-methylphenidate tablet Focalin Early peak, 4–6-hr duration 2nd dose at lunch Ages 6–17
Extended-release d-methylphenidate capsule Focalin XR Two peaks (after 1.5 and 6.5 hrs),
8–10-hr duration
Once-daily in the morning Ages 6–17 and adults
Immediate-release d,l-methylphenidate tablet Ritalin Early peak, 3–4-hr duration 2nd dose at lunch Ages 6–12 and adults
Immediate-release d,l-methylphenidate oral solution Methylin Early peak, 3–4-hr duration 2nd dose at lunch Ages 6 to 12
Extended-release d,l-methylphenidate tablet Ritalin SR
Methylin ER
Metadate ER
Early peak, 3–8-hr duration Lunch dosing may be needed Ages 6–17 and adults
Extended-release d,l-methylphenidate tablet Concerta Small early peak, 12-hr duration Once-daily in the morning Ages 6–17 and adults
Extended-release d,l-methylphenidate chewable tablet QuilliChew ER Peak at 5-hr, 8-hr duration Once-daily in the morning Ages 6–17 and adults
Extended-release d,l-methylphenidate capsule Metadate CD Strong early peak,
8-hr duration
Once-daily in the morning Ages 6–17
Extended-release d,l-methylphenidate capsule Ritalin LA Two strong peaks (early and at 4 hrs),
6–8-hr duration
Once-daily in the morning Age 6–12
Extended-release d,l-methylphenidate (capsule) Aptensio XR Up to 12-hr duration Once-daily in the morning Ages 6–17 and adults
Extended-release d,l-methylphenidate oral suspension Quillivant XR Peak at 5-hr, 12-hr duration Once-daily in the morning Ages 6–17 and adults
Extended-release d,l-methylphenidate transdermal patch Daytrana One peak at 7–10-hr, 12-hr duration Once-daily in the morning Ages 6–17
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immediate-release versus sustained-release (30/70,
40/60, or 50/50) in order to have greater delivery in
the morning or increased medication delivery in the
afternoon. Several triple-bead-release preparations are
in development, one of which will be a triple-release
methylphenidate formulation and one of which will be a
triple-beaded amphetamine salt preparation. Each of
these formulations will involve a percentage of beads that
is immediate-release in the stomach, another percentage
of beads that is released 4 hours later in the small
intestine, and another percentage of beads that is
released 8 hours later in the large intestine. These
formulations are designed with the intent to extend
duration of clinical efficacy for up to 16 hours.
A more recent adaptation of the beaded technology
involves a multilayered release technology, where each
bead has a 40% immediate-release outer coating with
the inner 60% of each bead composed of multiple
pH-dependent coatings, which dissolve as each bead
passes through various points in the intestinal tract.
This multilayered release profile results in a biphasic
pharmacokinetic curve, with an immediate first peak
2 hours post-dose and a second peak 8 hours post-dose.45
A new multilayered release formulation is being devel-
oped to extend the clinical duration from 12 to 16 hours.
Beyond beads
The OROS capsule provides a novel delivery system with
ongoing continuous release over 10–12 hours. After inges-
tion, stomach fluid is absorbed through osmotic pores in
one end of the capsule, causing medication to be excreted
through a laser-drilled hole at the other end of the capsule.46
A prodrug version of amphetamine was developed by
binding lysine to amphetamine.47 Lisdexamfetamine is a
hydrophilic, “biologically inactive” prodrug that is not able
to cross the bilipid blood–brain barrier. Lisdexamfetamine
is enzymatically cleaved into free amphetamine and free
lysine by enzymes in the cytosol of the human red blood
cells, which provides sustained symptomatic improvement
for 13 hours in children and 14 hours in adults.
Lisdexamfetamine can be dissolved in fluid such as juice
and administered as a liquid dose.
The ADHD field has one transdermal methylphenidate
option, which provides continuous transdermal release of
methylphenidate from the moment the patch is applied
with continued efficacy until approximately 2 hours after
the patch is removed.48 This allows flexibility of daytime
dosing, with shorter or longer wear times depending on the
individual needs of the patient (it can be worn as short as
several hours and as long as 9 to 12 hours). Unfortunately,
adverse effects such as rash and skin discomfort often
hinder the use of this transdermal technology, although it
should be noted that a transdermal amphetamine-based
patch currently in development may minimize some of the
associated skin reactions.
Microparticles
A variety of pH-based ion exchange polymers have been
developed to allow ion exchange of stimulant molecules
with underlying microparticle polymers.44 These pH-based
TABLE 4. Nonstimulant ADHD formulations
Formulations Brand names Duration Dosing Approval
Atomoxetine Strattera ~5-hour half-life Once or twice-daily; morning and late afternoon Ages 6–17 and adults
Guanfacine extended-release Intuniv ~14–18-hour half-life Once-daily in the morning Ages 6–17
Clonidine extended-release Kapvay 12–16-hour half-life Morning and night dosing Ages 6–17
TABLE 5. Drugs in development
Compound Mechanism/formulation Company Stage
SHP465 Amphetamine triple-beaded Shire Phase III complete
HLD-200 Methylphenidate Delexis technology—bedtime dosing Ironshore Phase III complete
NT0102 Oral dissolving mPH Neos Therapeutics Phase III complete
Dasotraline DA and NE reuptake inhibitor Sunovion Phase III
Centanafidine Triple reuptake inhibitor Neurovance Phase IIb complete
d-ATS Amphetamine transdermal system Noven Phase II complete
HLD-100 Amphetamine Delexis technology—bedtime dosing Ironshore Phase II
Edivoxetine NE reuptake inhibitor Lilly Phase II
Mazindol DA and NE reuptake inhibitor NLS Pharma Phase II
SPN810 (molindone) D2 antagonist Supernus Pharmaceuticals Phase II
SPN812 NE reuptake inhibitor Supernus Pharmaceuticals Phase II
mPH: methylphenidate, DA: dopamine, NE: norepinephrine.
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microparticle polymer technologies have allowed the
development of sustained-release liquid methylphenidate
and amphetamine preparations. The underlying micro
particles will not release the bound stimulant until the
microparticles absorb ions in the gastric lumen. These
liquid formulations offer sustained-release preparations
that can be titrated in small increments for childrenwho are
especially sensitive to side effects.49
An orally disintegrating tablet with a microparticle-
based, sustained-release amphetamine has recently
been developed. Each orally disintegrating tablet has
amphetamine molecules ionically bound to between
100,000 and 200,000 microparticles.50 A portion of these
microparticles begins to release stimulant immediately
when they encounter ions in gastric lumen; some of these
micorparticles are pH coated so that they will not release
the stimulant until they have passed into the small intestine.
A similar orally disintegrating methylphenidate preparation
is in development.
Two unique microparticle ADHD compounds in devel-
opment seek to provide both delayed onset and sustained
release. These delayed-onset, sustained-release preparations
of methylphenidate and amphetamine are dosed in the
eveningwith therapeutic onset upon awakening to avoid the
typical 1- to 2-hour therapeutic delay encountered with
morning administration of other ADHD stimulants.
Nonstimulants
Three nonstimulants are approved in the U.S. for ADHD
treatment. These options either block reuptake of
norepinephrine transporters (atomoxetine) or directly
stimulate the norepinephrine alpha 2a receptor
(guanfacine-XR and clonidine-XR). These options may
be utilized for individuals who cannot tolerate the
dopaminergic side effects of stimulants, require 24 hour
symptomatic coverage, or who have significant concerns
about abuse or diversion of stimulants. In addition, both
guanfacine-XR and clonidine-XR are approved for use in
combination with a stimulant for children who have
break-through symptoms on a stimulant alone.
In the pipeline
In addition to novel delivery systems, a number of new
molecules—both stimulant and nonstimulant—are in devel-
opment. A partial list would include the nonstimulants
dasotraline, viloxazone, centanafadine, and edivoxetine;
molindone-XR for aggression associated with ADHD; and
the long half-life stimulant mazindol.44
Summary
Our knowledge and understanding of the underlying
neurobiology and symptomatic expression of ADHD has
advanced dramatically within the U.S. and around the
world over the past decade. Associated with these
advances has been a similar explosion of new treatment
options to individualize treatment for our patients.
Optimal treatment today begins with measuring
and tracking ADHD symptoms with the goal of treating
to symptomatic remission with minimal functional
impairment. Individual clinical presentation and patient
response guide a clinician’s choice between chemical
classes of medications: methylphenidate, amphetamine,
or nonstimulant. Within both classes of stimulants,
we now have delivery systems that tailor the release
kinetics to optimize outcomes for each individual patient
with immediate-release, 8-hour sustained-release,
12- to 14-hour sustained-release, and, in the near
future, 16-hour sustained-release options. In addition,
2 delayed-onset, sustained-release ADHD medications
are currently in development, which offer the pros-
pect of improving early-morning symptoms. A deeper
understanding of the functional difficulties encountered
by ADHD patients throughout their lives, coupled with
more consistent use of ADHD rating scales, enable
clinicians to choose between a wide variety of medication
delivery systems in order to optimize the outcome for
each of their patients.
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NOTE: The posttest can only be submitted online. The below posttest questions have been provided solely as a study
tool to prepare for your online submission. Faxed/mailed copies of the posttest cannot be processed and will be
returned to the sender. If you do not have access to a computer, contact NEI customer service at 888-535-5600.
1. ADHD treatment is associated with:
A. Decrease in accidental injury and medical utilization due to accidents and trauma
B. Increase in accidental injury and medical utilization due to accidents and trauma
C. No change in accidental injury and medical utilization due to accidents and trauma
2. Studies have shown that combinations of non-stimulants with stimulants:
A. Can have beneficial effects for patients that were only partial responders to stimulant alone
B. Do not have any synergistic effect for patients that were only partial responders to stimulants alone
3. Research into the best ways to help differentiate between ADHD and bipolar disorder in children identified five
questions that best discriminate between the two disorders. Which of the following was NOTone of those questions?
A. Decreased need for sleep
B. Elated mood
C. Grandiosity
D. Hypersexuality and hypersexual behavior
E. Irritability
F. Racing thoughts
Optional CME Online Posttest and Certificate Instructions
There is no posttest fee nor fee for CME credits.
1. Read the article
2. Complete the posttest and activity evaluation, available only online at www.neiglobal.com/CME (under
“CNS Spectrums”)
3. Print your certificate, if a score of 70% or more is achieved
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